PCSK-9 Inhibitors: Basic Biology to Clinical Outcomes-PCSK-9 Inhibitors: Basic Biology to Clinical Outcomes

PCSK-9 Inhibitors: Basic Biology to Clinical Outcomes

Video Transcription

Video Summary

The video is a presentation by Connie Newman, an endocrinologist, on PCSK9 inhibitors and their role in cholesterol management. PCSK9 inhibitors are a class of drugs that work by reducing the LDL cholesterol in the body. Connie discusses the different options for LDL reduction, including statins, ezetimibe, and PCSK9 inhibitors. She explains that PCSK9 inhibitors can be added to statin therapy to further reduce LDL cholesterol levels. She also discusses the benefits and safety of PCSK9 inhibitors, as well as their cost and coverage considerations. Connie presents case studies to illustrate the use of PCSK9 inhibitors in clinical practice, including considerations for different patient populations, such as those with familial hypercholesterolemia. She concludes by summarizing the key points of her presentation and expressing gratitude to her colleagues and family.

Keywords

Connie Newman

endocrinologist

PCSK9 inhibitors

cholesterol management

LDL cholesterol

statins

ezetimibe

LDL reduction


EndoCareers \| Contact Us \| Privacy Policy \| Terms of Use	CONNECT WITH US
© 2021 Copyright Endocrine Society. All rights reserved.	2055 L Street NW, Suite 600 \| Washington, DC 20036 202.971.3636 \| 888.363.6274